TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11236832

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol with reinforcement (money and verbal approval)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol without reinforcement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Placebo with reinforcement (money and verbal approval)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo without reinforcement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9310521

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX) 0.15 mg/kg/dose
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg/dose
Number of subjects: 125

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 125

Group type: COMPARATOR
Intervention: Dexamphetamine (DEX) vs Methylphenidate (MPH)
Number of subjects: 125
Study: 8418717

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 300

Group type: COMPARATOR
Intervention: Citrate alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ranitidine/citrate
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ranitidine (given more than 30 min before PI sample)
Number of subjects: 300
Study: 3805657

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nightly)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sucralfate (2 g/day)
Number of subjects: 59
Study: 30961937

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1082
Study: 28727639

Group type: EXPERIMENTAL
Intervention: MCI-EX (12-week resistance exercise program with elastic band)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NG-EX (12-week resistance exercise program with elastic band)
Number of subjects: 22

Group type: COMPARATOR
Intervention: MCI-Con (control group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: NG-Con (control group)
Number of subjects: 22
Study: 27447948

Group type: EXPERIMENTAL
Intervention: Collaborative primary care for PTSD and depression
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Moderate combat exposure
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: High combat exposure
Number of subjects: 474
Study: 24749987

Group type: EXPERIMENTAL
Intervention: Theatre and surgical wards
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theatre and departmental office
Number of subjects: 16

Group type: COMPARATOR
Intervention: Restricted to theatre only
Number of subjects: 16
Study: 23130649

Group type: EXPERIMENTAL
Intervention: 100 μg GMZ2 vaccine in pre-school children
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine in vaccinated adults
Number of subjects: 2
Study: 20538749

Group type: EXPERIMENTAL
Intervention: Standard care plus OMM
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 34
Study: 17021884

Group type: EXPERIMENTAL
Intervention: Dolasetron 1 mg/kg body weight during surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 40
Study: 16206603

Group type: EXPERIMENTAL
Intervention: Quinapril (n=28)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Valsartan (n=26)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quinapril + Valsartan (n=26)
Number of subjects: 80
Study: 12431323

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based regimens)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 4
Study: 10901600

Group type: EXPERIMENTAL
Intervention: Composite posterior material with barium-aluminium silicate (radiopaque)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Composite posterior material without barium-aluminium silicate (not radiopaque)
Number of subjects: 137
Study: 7737712

Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 20 mg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 79
Study: 2390186

Group type: COMPARATOR
Intervention: Oral solution (OS) containing the concentrated official formula in packets (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Commercially prepared ready‐to‐use OS (group B)
Number of subjects: 100
Study: 7011359

Group type: EXPERIMENTAL
Intervention: RePUVA (retinoid plus PUVA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Retinoid alone (Tigason)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PUVA alone
Number of subjects: 80
Study: 31109126

Group type: EXPERIMENTAL
Intervention: Cascade Ensemble Learning (CELearning) model using XGBoost, Random Forest, ExtraTrees, and Softmax Regression; details on dosage and duration not applicable as this is a computational model.
Number of subjects: 0
Study: 27807887

Group type: EXPERIMENTAL
Intervention: Resveratrol 480 mg/day for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo capsules for 4 weeks
Number of subjects: 43
Study: 26019248

Group type: EXPERIMENTAL
Intervention: Casein dissolved in bovine milk serum (Cas+Serum)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Micellar casein only (Cas)
Number of subjects: 32
Study: 24121143

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (LR) 10^10 colony-forming units, 5 drops per day for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (LR)
Number of subjects: 61
Study: 21098476

Group type: EXPERIMENTAL
Intervention: 1-dose group (500 mg oral dose 2 hours before procedure)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 2-dose group (500 mg oral dose 2 hours before procedure and an additional dose 8 hours later)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Both groups (1-dose and 2-dose)
Number of subjects: 414
Study: 19943593

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 83

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 83
Study: 19199220

Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle brace
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no stabilizer)
Number of subjects: 20
Study: 15657411

Group type: EXPERIMENTAL
Intervention: Behavioral intervention grounded in social cognitive theory, consisting of five group sessions focused on enhancing motivation and developing coping efficacy skills.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 0
Study: 11935164

Group type: EXPERIMENTAL
Intervention: Intracameral injections of corticosteroids
Number of subjects: 28
Study: 10803113

Group type: EXPERIMENTAL
Intervention: Microfilled resin (Silux Plus, 3M, USA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hybrid minifilled composite resin (Herculite XRV, Kerr, USA)
Number of subjects: 28
Study: 7575694

Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxychloroquine 400 mg/day plus Piroxicam 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day
Number of subjects: 0
Study: 2403063

Group type: EXPERIMENTAL
Intervention: 50 micrograms vitamin D daily for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7013586

Group type: EXPERIMENTAL
Intervention: Levamisole as an adjunct to routine chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine chemotherapy for tuberculosis only (Control)
Number of subjects: 50
Study: 31340880

Group type: EXPERIMENTAL
Intervention: Maternal BMI at follow-up
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Snacking dietary pattern
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Cooked foods dietary pattern
Number of subjects: 889

Group type: COMPARATOR
Intervention: Gender comparison (Boys vs Girls)
Number of subjects: 889
Study: 29340678

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass + lifestyle-intensive medical management
Number of subjects: 120

Group type: COMPARATOR
Intervention: lifestyle-intensive medical management
Number of subjects: 120
Study: 26362593

Group type: EXPERIMENTAL
Intervention: Marginal mandibulectomy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glossectomy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Segmental mandibulectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 24136368

Group type: EXPERIMENTAL
Intervention: Oral glycerol
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both therapies (glycerol and acetaminophen)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 23304075

Group type: EXPERIMENTAL
Intervention: Group A: 10 mL of 0.5% bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B: 10 mL of 0.5% bupivacaine on one side and 10 mL of normal saline (NSS) placebo on the opposite side
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group C: 10 mL of NSS placebo per side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 20438534

Group type: EXPERIMENTAL
Intervention: Direct adsorption of lipoproteins (DALI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Heparin‐induced LDL‐precipitation (HELP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: LDL apheresis (all methods combined)
Number of subjects: 19
Study: 18356633

Group type: EXPERIMENTAL
Intervention: Conventional amikacin dosing
Number of subjects: 40
Study: 16544143

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5‐FU 750 mg/m2/day
Number of subjects: 15
Study: 12913205

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 110

Group type: COMPARATOR
Intervention: Electrophysiology
Number of subjects: 110
Study: 11286111

Group type: EXPERIMENTAL
Intervention: LASIK procedure
Number of subjects: 112
Study: 8911706

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levocabastine at 2 x 10(‐5) M concentration
Number of subjects: 10
Study: 1918421

Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg three times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg three times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venlafaxine 125 mg three times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7143458

Group type: EXPERIMENTAL
Intervention: Therapy focused on obtaining orgasm through self‐stimulation
Number of subjects: 4
Study: 31986526

Group type: EXPERIMENTAL
Intervention: Nurse home visits (NHVs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease management clinics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 31118458

Group type: EXPERIMENTAL
Intervention: SnCl2/AmF/NaF-containing mouth rinse and toothpaste
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 28759734

Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Milk and yogurt beverage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dairy and nondairy beverages
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All beverages
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dairy beverages
Number of subjects: 26

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 26
Study: 26192044

Group type: EXPERIMENTAL
Intervention: Quotations condition (90-min relevance intervention)
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Text condition (90-min relevance intervention)
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Control condition (waiting control)
Number of subjects: 1916
Study: 23591256

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 21326120

Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy for 4 weeks
Number of subjects: 45
Study: 19251872

Group type: EXPERIMENTAL
Intervention: Laughter (30-minute film segment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mental Stress (30-minute film segment)
Number of subjects: 18
Study: 18061058

Group type: EXPERIMENTAL
Intervention: Total cholesterol (1 mmol/L lower)
Number of subjects: 900000

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 900000

Group type: EXPERIMENTAL
Intervention: Total/HDL cholesterol ratio
Number of subjects: 900000
Study: 15134763

Group type: EXPERIMENTAL
Intervention: Event-related functional magnetic resonance imaging (fMRI) during attentional blink paradigm
Number of subjects: 0
Study: 11561919

Group type: EXPERIMENTAL
Intervention: Approach emotional state
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Withdrawal emotional state
Number of subjects: 152

Group type: COMPARATOR
Intervention: Neutral emotional state
Number of subjects: 152
Study: 9585795

Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg on day 15, 400 mg on day 16, and 500 mg on days 17 to 24)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rifabutin (150 mg daily for 24 days) with placebo
Number of subjects: 16
Study: 8148935

Group type: EXPERIMENTAL
Intervention: Spanish version of an educational program designed to be an adjuvant to adequate medical care
Number of subjects: 138

Group type: COMPARATOR
Intervention: Adequate care from the research staff (after trial termination)
Number of subjects: 138
Study: 3127076

Group type: EXPERIMENTAL
Intervention: Intravenous NTG combined with intravenous NAC (5 g 6 hourly)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous NTG alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravenous NTG and continuously infused NAC (10 g/day)
Number of subjects: 46
Study: 30138668

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 27347863

Group type: EXPERIMENTAL
Intervention: Leg strengthening group (IG); n = 19
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control group (CG); n = 17
Number of subjects: 40
Study: 26121725

Group type: EXPERIMENTAL
Intervention: Oral sucrose prior to echocardiography
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no oral sucrose)
Number of subjects: 104
Study: 23540865

Group type: EXPERIMENTAL
Intervention: Targeted biopsies using MRI/TRUS fusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Randomized biopsies
Number of subjects: 30
Study: 21712261

Group type: EXPERIMENTAL
Intervention: RVA+LV pacing mode
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: RVOT+LV pacing mode
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CRT (both RVA+LV and RVOT+LV)
Number of subjects: 33
Study: 19196911

Group type: EXPERIMENTAL
Intervention: Strength training combined with plyometric jumps (9 weeks)
Number of subjects: 66
Study: 16766440

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for blindness with increased brightness of the light during suggestion in Study 1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nonexperimental procedure in Study 2
Number of subjects: 43
Study: 15385695

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 11680282

Group type: EXPERIMENTAL
Intervention: Continuous Reinforcement (CRF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed Ratio (FR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable Ratio (VR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed Interval (FI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable Interval (VI)
Number of subjects: 0
Study: 9127855

Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tape bandage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ligafix brace
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Malleoloc brace
Number of subjects: 41

Group type: COMPARATOR
Intervention: No stabilizing device
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Single-leg jumping test
Number of subjects: 41
Study: 7946224

Group type: EXPERIMENTAL
Intervention: Guardianship networks
Number of subjects: 664

Group type: COMPARATOR
Intervention: No guardianship networks
Number of subjects: 664
Study: 3123132

Group type: EXPERIMENTAL
Intervention: Lng‐IUD
Number of subjects: 2758

Group type: COMPARATOR
Intervention: Nova T
Number of subjects: 2758
Study: 31169094

Group type: EXPERIMENTAL
Intervention: Parent training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maternal perceived self-efficacy and locus of control
Number of subjects: 30
Study: 29252040

Group type: EXPERIMENTAL
Intervention: Moderate Glycemic Index (MGI) diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 17
Study: 27491361

Group type: COMPARATOR
Intervention: Day-time compression garment alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Day-time compression garment + night-time compression bandaging
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Day-time compression garment + use of a night-time compression system garment
Number of subjects: 120
Study: 25600472

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HS)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: 15% hypertonic saline (HS)
Number of subjects: 444
Study: 22995323

Group type: EXPERIMENTAL
Intervention: SB‐656933 50mg once daily for 28 days
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: SB‐656933 20mg once daily for 28 days
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 21908943

Group type: EXPERIMENTAL
Intervention: Mayonnaise (MS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carrot Juice (JU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carrot with Oil (OIL)
Number of subjects: 9
Study: 19106506

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with S‐1 and cisplatin (IP group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Systemic chemotherapy with S‐1 and cisplatin (IV group)
Number of subjects: 8
Study: 16624457

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (first vaccination)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, first vaccination)
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (second vaccination)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, second vaccination)
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (third vaccination)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, third vaccination)
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (immunogenicity)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Encepur (immunogenicity)
Number of subjects: 3966
Study: 14648410

Group type: EXPERIMENTAL
Intervention: Methylene blue-directed biopsy (MBDB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 57
Study: 11498896

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63

Group type: COMPARATOR
Intervention: Piracetam (Control)
Number of subjects: 63
Study: 9798957

Group type: EXPERIMENTAL
Intervention: 50 Hz magnetic field (0.6 mT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Static magnetic field (0.6 mT)
Number of subjects: 16
Study: 8068472

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Captopril 100 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3181276

Group type: EXPERIMENTAL
Intervention: Platelet activating factor (PAF) 26 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29452685

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic stimulation plus medical therapy
Number of subjects: 251

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 251
Study: 27943563

Group type: EXPERIMENTAL
Intervention: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Retreatment with DCV-TRIO + RBV for 12 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with baseline HCV-RNA <2 million IU/mL
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with baseline HCV-RNA ≥2 million IU/mL
Number of subjects: 28
Study: 25302932

Group type: EXPERIMENTAL
Intervention: 4D MUSIC technique
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ferumoxytol-based first-pass CE-MRA
Number of subjects: 8
Study: 24168554

Group type: EXPERIMENTAL
Intervention: Vertebral fracture (classified by appearance, number, severity, and location)
Number of subjects: 2132

Group type: EXPERIMENTAL
Intervention: Adjusted FVC, FEV1, and FEV1/FVC values
Number of subjects: 2132

Group type: EXPERIMENTAL
Intervention: Obstructive and restrictive ventilatory impairment
Number of subjects: 2132
Study: 21174610

Group type: EXPERIMENTAL
Intervention: Tailored and dose-dense EC followed by docetaxel (arm A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fixed dose EC followed by docetaxel (arm B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin and cyclophosphamide (arm C)
Number of subjects: 124